Evidence map›Paper›PMID 39458578›Full record

ArticlePharmaceutics2024

An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles.

Jianxi Huang, Yu-Ting Chien, Qingxin Mu, Miqin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jianxi HuangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-1993-5792
Yu-Ting ChienDepartment of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Qingxin MuDepartment of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-4952-6591
Miqin ZhangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-8974-1494

Funding

Drug combination nanoparticles for advanced treatment of metastatic TNBCR21CA273739 · NCI · UNIVERSITY OF WASHINGTON · PI MU, QINGXIN · 2023 to 2024
$368k
National Institutes of Health: R01EB026890NCI NIH HHS R21 CA273739NIH HHS R21CA273739
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancerchemotherapyco-deliveryimmunotherapypolymeric nanoparticles

Identifiers

PMID39458578
PMCPMC11510515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.